急性冠脉综合征患者血清炎性标志物浓度变化及其临床意义

目的探讨血清炎性标志物与急性冠脉综合征(ACS)的关系。方法检测48例ACS患者血清C-反应蛋白(CRP)、可溶性血管内皮细胞黏附分子-1(sVCAM-1)和可溶性细胞间黏附分子-1(sICAM-1)等炎性因子变化,与冠脉造影结果和临床预后进行对比分析。结果1ACS组血清CRP与sICAM-1、sVCAM-1水平均高于稳定性心绞痛(SA)组和正常对照组;2sVCAM-1≥870ng/ml者3个月内主要冠脉不良事件(MACE)发生率明显高于<870ng/ml者;3血清肌钙蛋白阳性者CRP、sICAM-1、sVCAM-1浓度均明显高于阴性者;4冠脉狭窄程度在ACS组与SA组无统计学差异;冠脉狭窄程度积分与TC水平呈正相关,而与血清CRP、sICAM-1、sV-CAM-1及血浆纤维蛋白原(Fig)水平均无相关性;5sVCAM-1、Fig和肌钙蛋白预测3个月内MACE发生的敏感性分别为67.5%、82.4%、57.1%;特异性分别为54.8%、58.1%、81.5%。结论血清炎性标志物对ACS患者临床危险分层和判断预后有重要意义。     

系统性红斑狼疮患者血清黏附分子的表达及意义

采用流式细胞仪法测定了31例系统性红斑狼疮（SLE）患者（SLE组）血清可溶性细胞间黏附分子-1（slCAM-1）、可溶性血管细胞间黏附分子-1（sVCAM-1）水平，并与其他免疫学指标和对照组（18例健康体检者）上述指标进行相关性分析。结果SLE组slCAM-1、sVCAM-1水平明显高于对照组；活动期患者明显高于稳定期患者，有肾损害者明显高于非肾损害者，P均〈0．01。抗ds-DNA阳性者明显高于阴性者P〈0．01；二者与血沉呈正相关。认为血清slCAM-1、sVCAM-1在SLE发病中有重要作用。可作为判断SLE疾病活动的指标。     

原发性胆汁性肝硬化患者血清可溶性血管细胞黏附分子-1和可溶性细胞间黏附分子-1的表达及其临床意义

目的 检测原发性胆汁性肝硬化(PBC)患者血清中可溶性血管细胞黏附分子-1(sVCAM-1)及可溶性细胞间黏附分子-1(sICAM-1)的表达,并探讨其临床意义.方法用酶联免疫吸附法(ELISA)测定27例PBC患者及20例对照组血清sVCAM-1、sICAM-1的含量,分别比较PBC患者child-pugh分级各级别上述因子表达水平.结果 PBC患者血清sVCAM-1和sICAM-1水平明显高于对照组(P<0.05);child-pugh分级B、C级患者血清sVCAM-1和sICAM-1水平高于A级(P<0.05).结论sVCAM-1、sICAM-1参与了PBC的病理生理过程,与疾病分级相关,血清8VCAM-1、sICAM-1含量增高可作为原发性胆汁性肝硬化肝损害的判断指标.     

sICAM-1、sVCAM-1在急性动脉硬化性脑梗死中的临床意义

目的:探讨可溶性细胞间黏附分子-1(sICAM-1)及可溶性血管细胞间黏附分子-1(sVCAM-1)在急性动脉硬化性脑梗死中的临床意义。方法:研究对象分为急性脑梗死组(n=60例)及对照组(n=28例),检测所有受试者血清sICAM-1、sVCAM-1水平,分析二者与脑梗死面积及临床转归之间的关系。结果:急性脑梗死患者血清sICAM-1、sVCAM-1水平显著高于对照组(P<0.01),二者与梗死面积大小呈正相关;而不同转归组之间二者含量无显著差别。结论:sICAM-1、sVCAM-1参与脑梗死炎症过程,可预示脑梗死严重程度。     

系统性红斑狼疮患者可溶性黏附分子水平与中医辨证分型的关系

目的探讨可溶性黏附分子与系统性红斑狼疮（SLE）辩证分型的关系,指导SLE的中医辨证施治。方法采用ELISA法检测46例SLE患者（观察组）和20例健康体检者（对照组）血清可溶性细胞间黏附分子-1（sI-CAM-1）、血管内皮细胞黏附分子-1（sVCAM-1）水平。结果观察组sICAM-1、sVCAM-1水平明显高于对照组,P〈0.01;热毒炽盛、脾肾阳虚、肝肾阴虚型患者依次递减（P〈0.01）;热毒炽盛、脾肾阳虚型明显高于肝肾阴虚型（P〈0.01）。结论中医辨证分型结合sICAM-1、sVCAM-1检测水平有助于中医辨证分型并指导临床辩证施治。     

幽门螺杆菌感染患者血清可溶性黏附分子1(sICAM-1)检测研究

目的研究慢性胃病患者幽门螺杆菌(Helicobacter pylori,Hp)感染与血清可溶性黏附分子1(Soluble Intercellular Adhesion molecule-1,sICAM-1)水平关系。方法对205例慢性胃病患者进行了血清sICAM-1水平检测,并同时进行RUT、组织MB染色、Hp抗体和~(14)C-UBT四项方法检测Hp感染。结果胃粘膜Hp阳性组患者血清sICAM-1为889.43±22.52ng/m1,明显高于Hp阴性组患者747.07±30.45ng/ml(P<0.05);胃粘膜Hp感染菌量+、++、+++三组患者sICM-1水平分别为841.68±72.36ng/ml、905.43±37.59ng/ml和1012.54±49.34ng/ml,三组间差异显著(P<0.05);慢性胃炎、消化性溃疡患者血清sICAM-1水平明显高于正常对照组(P<0.05).结论胃粘膜Hp感染患者血清sICAM-1水平明显升高,血清sICAM-1水平可作为判断Hp感染新的感染免疫活动指标。     

胃癌患者血清sICAM-1、sVCAM-1和sFas水平的研究

目的:为了解胃癌患者血清中可溶性细胞间粘附因子-1(sICAM.1)、血管间粘附因子.1(sVCAM-1)和Fas受体(sFas)的水平变化 方法:用双抗体夹心ELISA法检测了32例胃癌患者及25名正常健康人血清sICAM-1、sVCAM-1和sFas水平 结果:发现胃癌患者sICAM-1和sVCAM-1水平明显高于正常健康人(289.25±32.69ng/ml比190.44±35.92ng/ml:1430.88±421.71ng/ml比727.24±157.68ng/ml),差异显著,且与临床分期有关。而胃癌患者血清sFas水平则明显低于正常健康人(8.55±2.45ng/ml比12.33±4.02ng/ml),差异显著(P<0.01).但与临床分期无关 结论:sICAM-1 sVCAM-1在胃癌的发生发展中起着重要作用,患者血清水平的测定,对病情、病期、预后的判断及治疗效果的观察均具有重要意义 而胃癌细胞与其他大部分肿瘤细胞不同.对sFas调节作用可能并不敏感。     

血清sICAM-l/sVCAM-l水平与上皮性卵巢癌关系的研究

目的 探讨血清可溶性细胞间黏附分子-1/血管细胞黏附分子-1(sICAM-1/sVCAM-1)在上皮性卵巢癌中的临床意义.方法 利用ELISA法检测健康妇女血清sICAM-1/sVCAM-1浓度并确定其血清正常值范围.同时测定良性卵巢肿瘤和上皮性卵巢癌患者血清sICAM-1/sVCAM-1浓度并分析其与上皮性卵巢癌患者临床病理资料的关系.结果 血清sICAM-1和sVCAM-1平均浓度和阳性率卵巢上皮癌组显著高于良性卵巢瘤组和正常对照组(P＜0.05);临床Ⅱ～Ⅳ期显著高于临床I期卵巢癌患者(P＜0.05);淋巴结转移阳性者显著高于淋巴结转移阴性者(P＜0.01);组织分化程度Ⅲ级显著高于I、Ⅱ级(P＜0.01);卵巢癌组术后显著低于术前(P＜0.005).而sICAM-1和sVCAM-1浓度和阳性率与卵巢癌病理组织学类型无关.单因素生存分析sICAM-1和sVCAM-1水平与患者不良预后有关;多因素生存分析sICAM-1和sVCAM-1水平与预后无关.结论 sICAM-1/sVCAM-1检测可能有助于监测和判断上皮性卵巢癌患者的病情.     

氟伐他汀对充血性心力衰竭患者血清sICAM-1和sVCAM-1的影响

目的:探讨氟伐他汀短期治疗对充血性心力衰竭(CHF)患者血清中可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)和肿瘤坏死因子α(TNF-α)水平的影响。方法:将97例CHF患者随机分为对照组(常规治疗组)和试药组(氟伐他汀组)。采用ELISA测定治疗前及治疗两周后血清中sICAM-1、sVCAM-1和TNF-α水平。结果:两种方法都可以明显降低血清sICAM-1、sVCAM-1和TNF-α水平(P0.05);试药组血清TNF-α水平降低更为显著(P0.05),但血清sICAM-1和sVCAM-1降低水平与对照组无显著差别。结论:在常规治疗基础上短期加用氟伐他汀治疗不能进一步降低CHF患者血清sICAM-1和sVCAM-1水平。     

活动性幼年特发性关节炎患者sICAM-1 sVCAM-1的表达及意义

目的测定各型活动性幼年特发性关节炎(JIA)患儿血清中可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管间黏附分子-1(sVCAM-1)、白细胞介素(IL)-1、IL-4、肿瘤坏死因子(TNF)-α水平,探讨sICAM-1、sVCAM-1与疾病活动、疾病分型以及疾病严重程度的关系。方法用酶联免疫吸附试验(ELISA)检测30例活动性JIA患儿与8名健康对照儿童sICAM-1、sVCAM-1水平;用放射免疫法(RIA)检测IL-1、IL-4、TNF-α水平。结果30例JIA患者血清中sICAM-1、sVCAM-1、IL-1、IL-4、TNF-α水平明显高于健康对照组(P<0.01);在各型JIA中sVCAM-1与血沉(ESR)、C反应蛋白(CRP)呈正相关(P<0.05或0.01);而sICAM-1仅在全身型及多关节型JIA患儿中与关节肿胀指数、夜间痛呈正相关(P<0.01),与炎性指标ESR、CRP等无关。结论JIA患者血清中sICAM-1、sVCAM-1、IL-1、IL-4、TNF-α水平显著升高,可能参与了JIA的发病过程,sVCAM-1、sICAM-1可与ESR、CRP一起作为判断病情严重性的指标,且可能与JIA分型有关。     

胃肿瘤患者循环可溶性细胞间粘附分子-1和血管细胞粘附分子-1

AIM To elucidate the biological and clinical significance of sICAM-1 and sVCAM-1 in patients with gastric cancer.METHODS The serum levels of soluble ICAM-1 and VCAM-1 were measured with sandwith enzyme immunoassay.RESULTS In gastric cancer patients, soluble ICAM-1 and VCAM-1 concentrations were significantly elevated in comparision with those of healthy subjects (289.23μg/L±32.69μg/L vs 190.44μ/L±35.92μg/L,1430.88μg/L±421.71μg/L vs 727.24μg/L±157.68μg/L, respectively, P＜0.01). The increment in serum sICAM-1 and sVCAM-1 concentrations correlated well with the staging of gastric cancer. The serum levels of sICAM-1 and sVCAM-1 in patients of Ⅲ-Ⅳ stages were higher than those of Ⅰ-Ⅱ stages (346.60μg/L±92.10μg/L vs 257.54μg/L±32.77μg/L, 1800.60μg/L±510.76μg/L vs 1262.81μg/L±236.73μg/L). The levels of sICAM-1 and sVCAM-1 were correlated significantly (r=0.49,P＜0.01). The sICAM-1 and sVCAM-1 levels correlated positively with alkaline phophatase (r=0.63,0.71,P＜0.001) and white cell count (r=0.52,0.43, P＜0.01); but correlated negatively with serum albumin (r=-0.41, -0.49, P＜0.01).CONCLUSION The measurement of circulating ICAM-1 and VCAM-1 may bring additional prognostic information for patients with gastric cancer in varying stages.INTRODUCTIONTumor growth and metastasis involves a variety of cell-cell and cell-extracellular matrix interactions mediated by cell adhesion molecules. Currently, a number of cell adhesion molecules, such as intercellular adhesion molecules-1 (ICAM-1), vascular cell adhesion molecules-1 (VCAM-1), etc. have been found.ICAM-1 and VCAM-1 are members of the immunoglobulin supergene family which are cytokine-induced glycoproteins (IL-1, TNFα and IFNγ). Both of them have five or seven extracellular immunoglobulin-like domains, a single transmembranous domain and a short cytoplasmic tail[1,2]. The natural ligand of ICAM-1 or VCAM-1 is LFA-1 (CD11a) and Mac-1 (CD11b) or VLA-4, respectively[3]. ICAM-1 is a widely distributed protein on a variety of tissues, and can be detected in many cells such as macrophage, T- and B-cells, or fibroblasts, endothelial and epithelial cells. VCAM-1 is also a widely distributed protein and is constitutively expressed on tissue macrophage, dentritic cells in lymphoid tissue and skin, as well as on bone marrow fibroblasts and epithelial cells. Expression of VCAM-1 is inducible on vascular endothelial cells under pathological conditions[4].Recently, soluble forms of several adhesion molecules including ICAM-1 and VCAM-1 were found in serum of normal donors[5]. Abnormally high levels of them have been described in some solid malignant tumors, leukemia, autoimmune disease, infectious disease, etc.The present study was carried out to measure the circulating levels of sICAM-1 and sVCAM-1 in gastric cancer before treatment was given and to study their correlation with clinical, histological and routine laboratory parameters.     

2型糖尿病相关因素与sICAM-1关系的探讨

为探讨2型糖尿病(DM)患者可溶性细胞间粘附分子(sICAM—1)水平变化及其与血糖代谢控制、胰岛素抵抗(IR)、血压(BP)、体重指数(BMI)的关系，采用酶联免疫吸附法测定51例2型DM患者及20例查体健康者的血清sICAM—1水平，同时检测其空腹胰岛素(FIN)、糖化血红蛋白(GHbAlc)、空腹血糖(FPG)、Bp、BMI。结果显示，2型DM患者血清sICAM—1显著高于正常对照组(P＜0．01)，且血清sICAM—1与BMI、GHbAlc及收缩压呈正相关，相关系数r分别为0．441、0．435、0．311，P＜0．01、0．01、0．05。提示2型DM血清sICAM—1水平升高可能由肥胖和高血糖引起，控制血糖、减轻体重有助于降低sICAM—1。     

血清可溶性细胞间黏附分子1、透明质酸水平与Graves眼病疾病活动性之间的关系

探讨可溶性细胞间黏附分子1( sICAM-1)和透明质酸(HA)能否反映Graves眼病(GO)的疾病活动性.用ELISA方法检测48例GO患者(眼病组)的sICAM-1、HA水平,同时检测30例单纯Graves甲状腺功能亢进患者作为对照组.与对照组相比,眼病组的血清sICAM-1、HA水平明显增高(P＜0.05);且眼病组活动期的血清sICAM-1、HA水平明显高于稳定期(P＜0.05).Pearson相关性分析显示眼病组的血清sICAM-1、HA水平均与眼病活动分数(CAS)呈显著正相关(r=0.53,P＜0.01;r=0.46,P＜0.01),且sICAM-1与HA亦呈正相关(r=0.31,P＜0.05).GO患者外周血sICAM-1、HA水平可作为评价GO活动性的指标.     

Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) are elevated in advanced stages of non-Hodgkin's lymphomas

The serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) were measured in 116 patients with non-Hodgkin's lymphomas (NHL) tested previously for soluble intercellular adhesion molecule-1 (sICAM-1). In contrast to Hodgkin's disease and chronic lymphocytic leukaemia, the sVCAM-1 levels in NHL patients were not significantly different from the levels of healthy controls (n = 31). However, sVCAM-1 was elevated in advanced stage disease, i.e. stages III + IV. Elevated serum levels of sVCAM-1 were associated with significantly poorer disease-free (p = 0.024) and overall (p = 0.02) survival. sVCAM-1 correlated poorly with other known prognostic variables (LDH, sTK and beta 2m) and with sICAM-1. None of the tested markers added prognostic information for disease-free survival independently of Ann Arbor stage and B-symptoms. The expression of VCAM-1 and ICAM-1 in tumour biopsies from 15 patients representing 7 different histologies were examined and compared with the serum levels of the soluble adhesion molecules. No correlation was found between the adhesion molecule expression by vascular endothelium and the corresponding serum levels.     

血清可溶性细胞间黏附分子-1在皮肌炎合并间质性肺病患者中的意义研究

目的 探讨血清可溶性细胞间黏附分子1 (sICAM-1)在皮肌炎合并间质性肺病(ILD)患者中的意义.方法 回顾性分析中国医科大学附属第一医院2018年1月至2020年2月50例确诊为皮肌炎的患者,按是否合并ILD分为ILD组和非ILD组.收集研究对象的临床资料并使用酶联免疫吸附测定(ELISA)法测量血清sICAM-...     

Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: relation to insulin resistance

OBJECTIVE: Intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are members of the immunoglobulin supergene family and play a central role in cell-to-cell and in cell-to-extracellular matrix-mediated immune responses. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide variety of immunological abnormalities. The relationship between soluble adhesion molecules and insulin resistance has been observed in different populations. However, the association of circulating levels of soluble cell adhesion molecules with insulin resistance and/or hyperinsulinemia in patients with SLE has not been extensively established. METHODS: We evaluated the relationship of soluble ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) to insulin resistance in 68 patients with SLE and 34 age-matched healthy controls. RESULTS: Patients with SLE had significantly higher fasting insulin levels, homeostasis model assessment insulin resistance (HOMA-IR), HOMA beta-cell, and plasma levels of sICAM-1 and sVCAM-1 than controls. SLE patients with HOMA-IR in the top quartile had the highest plasma levels of sICAM-1. However, there was no statistical difference in plasma levels of sVCAM-1 between patients in the respective quartiles of insulin sensitivity-related variables. Plasma levels of sICAM-1, but not sVCAM-1, were significantly correlated with fasting insulin (r = 0.327, p = 0.006), HOMA-IR (r = 0.278, p = 0.022), and HOMA beta-cell (r = 0.359, p = 0.003). In addition, fasting insulin was responsible for sICAM-1 variability in patients with SLE. CONCLUSION: The elevation of plasma levels of sICAM-1 was associated with a status of insulin resistance in patients with SLE.     

Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) are elevated in advanced stages of non-Hodgkin's lymphomas

Abstract: The serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) were measured in 116 patients with non-Hodgkin's lymphomas (NHL) tested previously for soluble intercellular adhesion molecule-1 (sICAM-1). In contrast to Hodgkin's disease and chronic lymphocytic leukaemia, the sVCAM-1 levels in NHL patients were not significantly different from the levels of healthy controls (n = 31). However, sVCAM-1 was elevated in advanced stage disease, i.e. stages III + IV. Elevated serum levels of sVCAM-1 were associated with significantly poorer disease-free (p = 0.024) and overall (p = 0.02) survival. sVCAM-1 correlated poorly with other known prognostic variables (LDH, sTK and β₂m) and with sICAM-1. None of the tested markers added prognostic information for disease-free survival independently of Ann Arbor stage and B-symptoms. The expression of VCAM-1 and ICAM-1 in tumour biopsies from 15 patients representing 7 different histologies were examined and compared with the serum levels of the soluble adhesion molecules. No correlation was found between the adhesion molecule expression by vascular endothelium and the corresponding serum levels.     

可溶性细胞间粘附分子-1和透明质酸水平在肝硬化患者中的临床意义

探讨血清可溶性细胞间粘附分子-1(sICAM-1)和透明质酸(HA)与肝硬化及肝损害的关系。用ELISA法检测正常人、肝炎肝硬化活动性、静止性患者血清ICAM-1。用RIA法测定正常人、肝硬化各期患者血清HA.1．肝硬化组血清ICAM-1和HA均显著高于正常人，两组间存在显著差异。2．两组肝硬化患者中sICAM-1、HA血清水平也存在显著差异。病情越重、血清ICAM-1和HA水平越高。两者与血清ALT、AST、总胆红素(TBil)、γ-转肽酶(GCT)、球蛋白(G)呈显著正相关，与血清胆碱酯酶(ChE)、白蛋白呈显著负相关。肝硬化患者sICAM-1和HA水平可作为判定肝硬化及肝损伤程度的指标。     

Circulating soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in immunocompetent and renal transplant patients: correlation with cytomegalovirus disease and renal function.

The plasma levels of the soluble adhesion molecules, soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1), were measured before and after transplantation in 26 renal transplant recipients, and in 173 longitudinally collected samples in 17 of the patients. The patients were carefully monitored for the presence of cytomegalovirus (CMV) infection and rejection. Forty healthy blood donors and 12 otherwise healthy subjects with symptomatic primary CMV infections served as controls. During CMV disease, plasma levels of sVCAM-1 and sICAM-1 were elevated in both renal transplant patients and otherwise healthy subjects with CMV disease. The sVCAM-1 levels were strongly elevated before transplantation in renal transplant recipients and correlated with creatinine levels. Increased sVCAM-1 levels were also registered during rejection episodes. CMV disease, per se, is associated with markedly increased levels of sVCAM-1 and sICAM-1. There is also a correlation of sVCAM-1 levels with serum creatinine levels. Thus, the presence of CMV infection and renal function are factors that must be considered in further studies of soluble adhesion molecules.